Author

C. Gravekamp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Beck· 2 shared B. C. Selvanesan· 2 shared K. Meena· 2 shared A. Jahangir· 1 shared A. Ouedraogo· 1 shared A. Patel· 1 shared D. Chandra· 1 shared D. Entenberg· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Beck

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Immunotherapy for ovarian cancer is improved by tumor targeted delivery of a neoantigen surrogate

L. R. Scanlon, L. Gabor, O. R. Khouri, S. Ahmad, E. Levy, E. Buckley, A. Ouedraogo, D. Y.-S. Kuo, K. Lin, N. Nevadunsky, S. Isani, S. Sun, C. Gravekamp

This study shows that delivering a neoantigen surrogate via Listeria monocytogenes combined with gemcitabine and anti-PD1 improves ovarian cancer treatment in mice.

bioRxiv · Oct 11, 2023 · PreprintCancer Biology

Tumor-targeted delivery of childhood vaccine recall antigens by attenuated Listeria reduces pancreatic cancer

B. C. Selvanesan, D. Chandra, W. Quispe-Tintaya, A. Jahangir, A. Patel, K. Meena, R. Alberto Alves Da Silva, M. Friedman, J. Li, S. Siddiqui, S. K. Libutti, Z. Yuan, A. Beck, L. Tesfa, W. Koba, , C. Gravekamp

This study shows that delivering a childhood vaccine antigen via attenuated Listeria improves immunotherapy for pancreatic cancer by converting cold tumors into hot tumors and enhancing T cell activity.

bioRxiv · Jun 4, 2021 · PreprintImmunology

Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice

B. C. Selvanesan, K. Meena, A. Beck, L. Meheus, O. Lara, I. Rooman, C. Gravekamp

This study shows that combining nicotinamide with gemcitabine reduces pancreatic tumor growth and improves survival in mice by modulating the immune microenvironment.

bioRxiv · Jun 2, 2020Immunology